Cabozantinib, specific for a wide range of TKs, such as MET, RET, and VEGFR-2, is also an FDA-approved drug for metastatic medullary thyroid cancer and renal carcinoma, with antitumor effects in liver cancer, as assessed through phase II and phase III trials.333–335 Similarly, an exciting antitumor performance of cabozantinib was observed in research based on CRC xenograft models and cell lines, while the results from CRC-focused clinical trials are awaited.289,336,337. Here, MET is linked to renal carcinoma.